Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
PaizaBio reports on drug development and manufacturing strategies
December 17, 2015
By: David Deere
Chief Commercialization Officer, PaizaBio
China’s Food and Drug Administration (cFDA) has recently published long anticipated reforms designed to accelerate the regulatory review of new drugs and expand options for manufacturing those approved. The new policies, which went into effect December 1, are posted on cFDA’s website, and will impact both Chinese and Western pharmaceutical companies. The reforms represent major changes in China’s drug development and commercialization policies, addressing critical areas: accelerating the high-volume backlog of drugs awaiting review and approval by the cFDA and fostering domestic clinical drug development and manufacturing to international technical and quality standards. Streamlining Drug Review Streamlining the review of innovative new drugs is a top priority of the cFDA given growing public health issues that stand to benefit from effective pharmaceutical treatments. The new regulatory policy significantly expands the types of drugs that may qualify for a streamlined review process via the Fast Track or green approval pathway and redefines what qualifies as a new drug. Prior to the policy change, the Fast Track regulatory approval pathway was limited to novel drugs not approved for use anywhere in the world or drugs addressing areas of critical and high unmet medical need. The following drug categories stand to benefit from China’s redefined Fast Track regulatory approval pathway: · Pediatric/geriatric drugs; · Drugs sponsored by national science and technology related grants; · Drugs to treat diseases or conditions prevalent in China; · Foreign innovative drugs manufactured locally in China; · Foreign drugs manufactured at a U.S.-FDA or EU-EMA qualified plant under review by the respective regulatory authorities (FDA/EMEA) for concurrent marketing authorizations; and · Innovative drugs using advanced technology, using innovative treatment protocols or having significant clinical benefit. Fast Track approval will be permitted if a drug falls in one of these categories, and a clinical trial application is submitted three years prior to the date of patent expiration or the marketing authorization application is submitted one year prior to the date of patent expiration. Redefining “new” The new policies also seek to clarify what constitutes a “new” drug. The cFDA now defines new drugs as only those pharmaceutical products that have never been marketed anywhere in the world or those that represent an improved form of the new drug. Generic drugs are defined as pharmaceutical products that are consistent with the reference or originator drug in terms of quality or efficacy. The cFDA plans to introduce a classification system to address these new definition categories. To facilitate clinical development of new drugs in China, the cFDA clinical trial application process will be streamlined; a single umbrella approval will replace the current system requiring approval at each phase of a trial. Expanding Manufacturing Options Historically, only China-based drug manufacturers could apply for approval to market new drugs in China. Drug research organizations without large scale manufacturing capabilities were required to transfer new drug innovations to a manufacturer that would then become the Marketing Authorization Holder (MAH). This mandatory transferal of marketing rights created a disincentive for innovation and commercialization by research-based organizations at a time when China is focusing on building a more innovation-driven economy. The new policy now enables research-based organizations to commercialize their innovations while retaining marketing rights. As part of this development, China is launching a pilot MAH program in ten Chinese provinces allowing research-based organizations and individuals to outsource drug manufacturing to a contract manufacturing organization (CMO), while retaining marketing authorization status on approved drugs. Impact on Multinational Pharma China’s policy changes have the potential to significantly impact the global clinical development and manufacturing strategies of multinational pharmaceutical companies operating in China, said Stuart Rose, founder and chief executive officer of PaizaBio, a company focused on helping western-based pharmaceutical companies manufacture drugs in China for the Chinese market. Mr. Rose is currently in China as a featured speaker at the 2015 China National Science and Technology Cooperation Week in Dongguan City, as a guest of Tsinghua University’s Donguan Innovation Center. “With 1.4 billion people, China represents the largest drug market in the world. Yet western pharmaceutical companies have only a small foothold,” Mr. Rose said. “This is largely because China is a complicated environment for western companies in which to operate. These new policies reflect China’s growing willingness to engage multinationals in their drug development initiatives and allow contract manufacturing of new drugs in China for the Chinese market.” Mr. Rose added, “Entering China is not easy; the new policies reflect China’s intent to be an active participant in global drug development and commercialization. That will make manufacturing in China for the Chinese market through a CMO like PaizaBio an attractive way to comply with cFDA policies and gain immediate access to China’s 1.4 billion citizens.” Sources: cFDA Announcement on 11/5/2015 of the Pilot Program for MAH http://www.sfda.gov.cn/WS01/CL0051/133921.html cFDA Announcement on 11/13/ 2015 of Plans on Dealing with Backlog of Regulatory Filings http://www.sfda.gov.cn/WS01/CL0050/134823.html David Deere is a veteran global pharmaceutical professional with product, line, and operational management roles with major multinational, specialty multinational, and small organizations based in the United States and abroad. Prior to joining PaizaBio, David served as vice president, Worldwide Marketing and Regulatory Affairs for Valeant Pharmaceuticals International. While at Valeant, he helped triple the company’s turnover and capitalization value and expanded its geographic presence through acquisitions with operations in 14 countries and a direct sales force in 30. He also served as global therapeutic head, ID/Virology, F. Hoffman-La Roche, AG, in Basel, Switzerland, and product director, Anti-Infectives, Genentech (formerly Roche Labs).
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !